The pathologist and toxicologist in pharmaceutical product discovery

被引：9

作者：

Alden, CL ^{[1
]}

Sagartz, JE ^{[1
]}

Smith, PF ^{[1
]}

Wilson, AG ^{[1
]}

Bunch, RT ^{[1
]}

Morris, DL ^{[1
]}

机构：

[1] Monsanto Co, Life Sci, St Louis, MO 63167 USA

来源：

TOXICOLOGIC PATHOLOGY | 1999年 / 27卷 / 01期

关键词：

pathologist; toxicologist; pharmaceutical discovery; efficacy models;

D O I：

10.1177/019262339902700119

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Significant change is occurring in the drug discovery paradigm; many companies are utilizing dedicated groups from the toxicology/pathology disciplines to support early stage activities. The goal is to improve the efficiency of the discovery process for selecting a successful clinical candidate. Toxicity can be predicted by leveraging molecular techniques via rapid high-throughput, low-resource in vitro and in vivo test systems. Several important activities help create a platform to support rapid development of a new molecular entity. The proceedings of this symposium provide excellent examples of these applied concepts in pharmaceutical research and development. Leading biopharmaceutical companies recognize that a competitive advantage can be maintained via rapid characterization of animal models, the cellular identification of therapeutic targets, and improved sensitivity of efficacy assessment. The participation of the molecular pathologist in this quest is evolving rapidly, as evidenced by the growing number of pathologists that interact with drug discovery organizations.

引用

页码：104 / 106

页数：3

共 4 条

[1]

Balwierz P. S., 1998, Environmental and Molecular Mutagenesis, V31, P3

[2] Analysis of cytochrome P450 and phase II conjugating enzyme expression in adult male rat hepatocytes [J].